Q-omics provides the consensus-scored MCRS1 profile across patient tissues and cancer cell-line models. MCRS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MCRS1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, MCRS1 RNA expression shows 19,113 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where MCRS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MCRS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MCRS1 survival associations across molecular data types. MCRS1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MCRS1 RNA expression–survival associations across cancer types. High MCRS1 expression shows unfavorable associations in UVM, LIHC, ACC, MESO, LGG and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MCRS1 RNA expression.
This table summarizes MCRS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MCRS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MCRS1 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, LIHC, BLCA and KIRP. The COAD box plot shows higher MCRS1 RNA expression in tumor versus normal tissue (log2 FC = +0.687, t-test p < 0.001).
This table shows molecular features associated with MCRS1 in patient tissues and cancer cell lines. In patient samples, MCRS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MCRS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
